Six weeks of positive results in Phase III trials with the fixed-dose combination (FDC) of perindopril arginine with amlodipine besylate for high blood pressure should be enough – when packaged with data from overseas, where it's marketed already as Coveram – to justify a new drug application (NDA), said XOMA Corp.